Related Experiment Video
Updated: Jul 4, 2025
Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors
Vanessa Klapp1, Norma Bloy2, Carlos Jiménez-Cortegana2
1Department of Radiation Oncology, Weill Medical College of Cornell University, New York, NY, United States; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg, Institute of Health, Luxembourg, Luxembourg; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Abstract:
Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (i.e., palbociclib, abemaciclib, and ribociclib) are well known for their capacity to mediate cytostatic effects by promoting cell cycle arrest in the G1 phase, thus inhibiting cancer cell proliferation. Cytostatic effects induced by CDK4/6 inhibitors can be transient or lead to a permanent state of cell cycle arrest, commonly defined as cellular senescence. Induction of senescence is often associated to metabolic modifications and to the acquisition of a senescence-associated secretory phenotype (SASP) by cancer cells, which in turn can promote or limit antitumor immunity (and thus the efficacy of CDK4/6 inhibitors) depending on SASP components. Thus, although accumulating evidence suggests that anti-cancer effects of CDK4/6 inhibitors also depend on the promotion of antitumor immune responses, assessing cell cycle arrest and progression in cells treated with palbociclib remains a key approach for investigating the efficacy of CDK4/6 inhibitors. Here, we describe a method to assess cell cycle distribution simultaneously with active DNA replication by flow cytometry in cultured hormone receptor-positive breast cancer MCF7 cells.
Insights
Cyclin-dependent kinase 4/6 inhibitors induce cell cycle arrest and senescence, impacting cancer immunity. This study presents a flow cytometry method to assess cell cycle distribution and DNA replication in breast cancer cells treated with palbociclib.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors like palbociclib cause cell cycle arrest and senescence.
- Cellular senescence can lead to a senescence-associated secretory phenotype (SASP), influencing antitumor immunity.
- Understanding CDK4/6 inhibitor efficacy involves assessing cell cycle progression and immune response.
Purpose of the Study:
- To develop a method for assessing cell cycle distribution and DNA replication simultaneously.
- To investigate the effects of palbociclib on hormone receptor-positive breast cancer cells.
- To provide a tool for evaluating CDK4/6 inhibitor efficacy in cancer research.
Main Methods:
- Flow cytometry was employed to analyze cell cycle distribution.
- Active DNA replication was assessed concurrently with cell cycle phases.
- Cultured hormone receptor-positive breast cancer MCF7 cells were used as the model system.
Main Results:
- The described method allows simultaneous assessment of cell cycle distribution and DNA replication.
- This technique can be applied to study the effects of CDK4/6 inhibitors on cancer cells.
- Provides a quantitative approach to evaluate drug-induced cell cycle arrest and senescence.
Conclusions:
- Assessing cell cycle arrest and progression is crucial for understanding CDK4/6 inhibitor efficacy.
- The developed flow cytometry method offers a robust approach for such assessments.
- This technique aids in the investigation of cancer cell responses to CDK4/6 inhibitors and their impact on antitumor immunity.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:23Flow Cytometry
In...